摘要
目的探讨P-糖蛋白（P-gp）、多药耐药相关蛋白（MRP1）、乳腺癌耐药蛋白（BCRP）在非小细胞肺癌（NSCLC）组织中表达与患者临床病理特征和预后的关系。方法采用免疫组织化学SP法检测66例临床资料完整的NSCLC患者肿瘤组织中3种耐药蛋白的表达情况,分析耐药蛋白表达与患者临床病理特征和预后的关系。结果P-gp、MRP1和BCRP在NSCLC组织中总阳性表达率分别为40.91%、72.73%和43.94%,P-gp的表达分别与性别、年龄、吸烟史、病理类型相关;MRP1的表达与病理类型相关;BCRP的表达与年龄相关。患者整体生存时间与TNM分期和P-gp、MRP1共同表达有关;腺癌组患者生存时间与TNM分期和P-gp表达有关。结论P-gp和MRP1可以作为预测NSCLC患者预后的指标,BCRP的表达和预后无关。
Objective To investigate the relationship among the expression of three multidrug resistance proteins [ P - glycoprotein（ P - gp）, muhidrug resistance protein 1 （ MRP1 ） and breast cancer resistance protein （BCRP） ], patients＇ prognosis and clinicopathological featuresion non -small cell lung cancer （NSCLC）. Methods P - gp, MRP1 and BCRP were examined in 66 cancer samples from untreated NSCLC patients using immunohistochemistry. The prognosis and clinicopathological features were studied in relation to the expression of each of these proteins. Results P - gp, MRP1 and BCRP were highly expressed in 40. 91% , 72.73% and 43.94% of all cases, respectively. P-gp expression was associated with gender, age, smoking and histology. MRP1 expression was significantly greater in adenocarcinoma than in squamous cell carcinoma. There was no significant correlation between BCRP expression and the clinicopathological features. Significant associations were found among the patients＇ overall survival time and P - gp and MRP1 co - expression, as well as the stage. The overall survival time was associated with the TNM stage and P - gp expression in the adenocarcinoma group. Conclusion Increased expression of P - gp and MRP1 appears to be a predictor of prognosis in NSCLC patients, whereas BCRP expression was not associated with prognosis.
出处
《中原医刊》
2007年第7期1-5,共5页
Central Plains Medical Journal
关键词
P-糖蛋白
多药耐药相关蛋白
乳腺癌耐药蛋白
免疫组织化学
非小细胞肺癌
P - glycoprotein
Muhidrug resistance proteinl
Breast cancer resistance protein
Immunohistochemistry
Non -small cell lung cancer
